Answers are grounded in this paper and cite their sources.
Demonstrates a new scalable synthesis for enantiopure Edelfosine, suggesting improved availability for therapy.
The synthetic alkyl-lysophospholipid (ALP) Edelfosine has garnered attention due to its potent in vivo activity, oral administration route, and synergistic effects with other therapies. Its development as a preclinical candidate, however, is constrained by challenges associated with the economical, large-scale preparation of the enantiopure compound. Herein, we describe the development of a novel synthetic route that provides enantiopure (S)-Edelfosine in a scalable manner, amenable to industrial implementation. Through several iterations, we achieve synthetic improvements via a more convergent assembly of the substituted glycerol portion of the title compounds. By exploiting a chiral benzylglycidyl ether as the key synthon, we demonstrate the successful four-step, formal, and total syntheses of (S)- and (R)-Edelfosine respectively─the shortest demonstrably scalable routes of their kind. Finally, we establish phenyl trimethylammonium iodide as a suitable green alternative to carcinogenic iodomethane in this context. Our streamlined chiral pool approach thus furnishes a significant improvement in the synthetic accessibility of optically pure Edelfosine and paves the way for the parallel development of both medicinally relevant ALP enantiomers.
No takes yet. Share an insight, caveat, or question.
Soudani et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: